SNPs within CHRNA5-A3-B4 and CYP2A6/B6, nicotine metabolite concentrations and nicotine dependence treatment success in smokers
Language English Country Czech Republic Media print-electronic
Document type Journal Article
PubMed
31796940
DOI
10.5507/bp.2019.058
Knihovny.cz E-resources
- Keywords
- CYP2A6/B6, EGLN2, cotinine, hydroxycotinine, intensive treatment, nicotine metabolism, nicotine-acetylcholine receptors, smoking, tobacco dependence,
- MeSH
- Cytochrome P-450 CYP2A6 genetics MeSH
- Cytochrome P-450 CYP2B6 genetics MeSH
- Adult MeSH
- Polymorphism, Single Nucleotide * MeSH
- Middle Aged MeSH
- Humans MeSH
- Nicotine blood metabolism MeSH
- Receptors, Nicotinic genetics MeSH
- Tobacco Use Disorder blood genetics metabolism therapy MeSH
- Nerve Tissue Proteins genetics MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- CHRNA5 protein, human MeSH Browser
- CYP2A6 protein, human MeSH Browser
- CYP2B6 protein, human MeSH Browser
- Cytochrome P-450 CYP2A6 MeSH
- Cytochrome P-450 CYP2B6 MeSH
- Nicotine MeSH
- Receptors, Nicotinic MeSH
- Nerve Tissue Proteins MeSH
AIM: Plasma values of nicotine and its metabolites are highly variable, and this variability has a strong genetic influence. In our study, we analysed the impact of common polymorphisms associated with smoking on the plasma values of nicotine, nicotine metabolites and their ratios and investigated the potential effect of these polymorphisms and nicotine metabolite ratios on the successful treatment of tobacco dependence. METHODS: Five variants (rs16969968, rs6474412, rs578776, rs4105144 and rs3733829) were genotyped in a group of highly dependent adult smokers (n=103). All smokers underwent intensive treatment for tobacco dependence; 33 smokers were still abstinent at the 12-month follow-up. RESULTS: The rs4105144 (CYP2A6, P<0.005) and rs3733829 (EGLN2, P<0.05) variants were significantly associated with plasma concentrations of 3OH-cotinine and with 3OH-cotinine: cotinine ratios. Similarly, the unweighted gene score was a significant (P<0.05) predictor of both cotinine:nicotine and 3OH-cotinine:cotinine ratios. No associations between the analysed polymorphisms or nicotine metabolite ratios and nicotine abstinence rate were observed. CONCLUSION: Although CYP2A6 and EGLN2 polymorphisms were associated with nicotine metabolism ratios, neither these polymorphisms nor the ratios were associated with abstinence rates.
References provided by Crossref.org
